

CARCINOMES NASOPHARYNGES


ANTI PD1 COMBO CHIMIO

1^{ère} LIGNE R/M

CAPTAIN Zhang et al., ASCO 2021



Study Design (NCT03707509)



- Primary endpoint: independent review committee (IRC)-assessed PFS
- Secondary endpoints: investigator-assessed PFS, ORR, DCR, DoR, OS and safety

©2021 Eastern Cooperative Oncology Group (ECOG), National Cancer Institute (NCI), and National Cancer Institute (NCI). All rights reserved. ECOG is a trademark of the Eastern Cooperative Oncology Group (ECOG). DoR: duration of response

CARCINOMES NASOPHARYNGES


ANTI PD1 COMBO CHIMIO

1^{ère} LIGNE R/M

CAPTAIN Zhang et al., ASCO 2021



PFS per IRC



- Camrelizumab plus GP improved PFS compared with placebo plus GP, with a 48% lower risk of disease progression or death.

CARCINOMES NASOPHARYNGES

ANTI PD1 COMBO CHIMIO 1^{ère} LIGNE R/M

CAPTAIN Zhang et al., ASCO 2021



ASCO 2021
SFCFCF
Société Française de
Cancérologie Cervico-Faciale


Response Summary

	Camrelizumab plus GP (N = 134)	Placebo plus GP (N = 129)
Best overall response, n (%)		
CR	7 (5.2)	2 (1.6)
PR	111 (82.0)	102 (79.1)
SD	11 (8.2)	10 (7.7)
PD	3 (2.2)	4 (3.1)
NA	3 (2.2)	3 (2.3)
ORR		
% (95% CI)	88.1 (81.3-93.0)	80.6 (72.7-87.1)
Treatment difference, % (95% CI)	7.4 (-1.3-18.2); P = 0.1083	

Overall Survival

	Camrelizumab plus GP (N = 134)	Placebo plus GP (N = 129)
Events, n (%)	28 (20.9)	38 (29.5)
Median (95% CI), months	NR (NR-NR)	22.6 (19.2-NR)
Hazard ratio (95% CI)	0.87 (0.41-1.11); P = 0.0576	
12-month rate, % (95% CI)	85.0 (77.7-90.1)	83.4 (75.6-90.6)
24-month rate, % (95% CI)	70.0 (53.5-81.4)	NR (NR-NR)

Treatment-related Adverse Events



CARCINOMES NASOPHARYNGES

ANTI PD1

CONCLUSIONS

- Pas de bénéfice en monothérapie chez les patients pré traités par platine en termes de survie globale, taux de réponse, survie sans progression
- Bénéfice en termes d'effets secondaires
- Place dans la stratégie globale (car tox de la chimio...)
- Détermination de facteurs prédictifs de réponse / biomarqueurs


- Combo anti-PD1 chimio : 2 phases III avec bénéfice mais pas de maintenance dans le bras chimio
- Meilleure séquence à définir

AUTRES TUMEURS RARES ACSE NIVO

Essai clos aux inclusions

Inclusions tumeurs sino nasales et tumeurs des glandes salivaires non CAK

Nivolumab 3mg / kg / 2 sem



53^E CONGRÈS SFCCF 2021

CONGRÈS DE LA SOCIÉTÉ FRANÇAISE DE CARCINOLOGIE CERVICO-FACIALE



CONTACT :



caroline.even@gustaveroussy.fr



GUSTAVE /
ROUSSY
CANCER CAMPUS
GRAND PARIS



MERCI POUR VOTRE ATTENTION